Clinical Trials Browser

Phase 1/2 × Melanoma × GSK2636771 × Clear all

NCT03131908 2025-12-15

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Phase 1/2 Active not recruiting

Melanoma